Filing Overview
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. on February 16, 2021, reporting events occurring primarily on February 9–12, 2021. The provided metadata identifies GRI Bio, Inc., but the filing registrant is Vallon Pharmaceuticals, Inc. The filing concerns a public equity offering, related warrants, debt conversion, and corporate charter and bylaw amendments. It does not provide a quarterly or annual financial reporting period.
Key Financial and Capitalization Matters
- Public offering: The company sold 2,250,000 shares of common stock at a public offering price of $8.00 per share.
- Gross proceeds: $18.0 million.
- Net proceeds: Approximately $16.4 million after underwriting commissions and offering expenses.
- Underwriter option: The underwriters received a 45-day option to purchase an additional 337,500 shares at $7.44 per share, representing the offering price less the underwriting discount. The filing does not state whether the option was exercised.
- Representative’s warrants: Warrants to purchase 112,500 shares were issued with an initial exercise price of $10.00 per share. They are exercisable from August 11, 2021 through February 12, 2026.
- Debt conversion: Convertible promissory notes held by SALMON Pharma GmbH and CEO David Baker converted into 54,906 shares. The conversion price was equal to 80% of the $8.00 public offering price, or $6.40 per share.
- Operating performance: The filing does not provide revenue, net income or loss, cash-flow, margin, debt-balance, or liquidity metrics beyond the offering proceeds.
Material Changes and Corporate Actions
- A one-for-40 reverse stock split of the common stock became effective on February 10, 2021.
- The amended and restated certificate authorized 250,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
- The restated certificate established a three-class classified board, supermajority voting requirements for certain bylaw amendments and director removals, and an exclusive Delaware Court of Chancery forum for certain proceedings.
- Amended and restated bylaws became effective immediately before the offering closing and addressed stockholder proposals, director nominations, and conformity with the restated certificate.
Outlook, Risks and Unusual Items
- The filing does not provide formal financial guidance, operating forecasts, or management commentary regarding the use of proceeds.
- The offering diluted existing stockholders and the representative’s warrants may create additional future dilution if exercised.
- The company agreed to customary indemnification obligations in favor of the underwriters for certain securities-law liabilities.
- Investment banking affiliates of certain underwriters have provided, and may provide, services to the company for customary fees and expenses.
- The filing contains a timing inconsistency: it states that the offering closed on February 12, 2021, while the Item 3.02 discussion states that the offering closed on January 12, 2021. The January 12 reference appears inconsistent with the other disclosed dates and should be verified against the exhibits.
Facts Investors Should Verify
- Confirm the correct registrant and whether this filing is relevant to GRI Bio, Inc., since the filing names Vallon Pharmaceuticals, Inc.
- Verify the actual offering closing date and the apparent January 12/February 12 discrepancy.
- Determine whether the 337,500-share over-allotment option was exercised.
- Review the final share count and capitalization after the reverse split, public offering, debt conversion, and warrant issuance.
- Review the underwriting agreement, warrant form, amended charter, and bylaws for detailed rights, obligations, and dilution terms.